Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase–mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARγ agonist that improves insulin sensitivity, on lipoprotein metabolism in patients with T2DM. Pio treatment reduced TG levels by increasing the fractional clearance rate (FCR) of VLDL TGs from the circulation, without changing direct removal of VLDL particles. This indicated increased lipolysis of VLDL TGs during Pio treatment, a mechanism supported by our finding of increased plasma LPL mass and decreased levels of plasma apoC-III. Lower apoC-III levels were due to reduced apoC-III PRs. We saw no effects of Pio on the PR of either VLDL TG or VLDL apoB. Thus, Pio, a PPARγ agonist, reduced VLDL TG levels by increasing LPL mass and inhibiting apoC-III PR. These 2 changes were associated with an increased FCR of VLDL TGs, almost certainly due to increased LPL-mediated lipolysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 2×
“gene expression is suppressed by PPARα agonists (67), possibly via direct binding of activated PPARα, in a nonproductive manner, to a hepatocyte nuclear factor-4 site in the apoC-III promoter (68, 69).”
BackgroundInsulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Self-citationSchoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173 · cited 1×
“LPL is a PPARγ-responsive gene (56), and the PPARγ agonist troglitazone has been demonstrated to increase postheparin plasma LPL activity (57) and both preheparin (58) and postheparin (59) LPL mass in subjects with diabetes and/or insulin resistance.”
BackgroundAn Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 2×
“ApoA-V is a recently identified apolipoprotein that appears to play an important role in TG metabolism (21), and several studies have shown that polymorphisms in the apoA-V gene are associated with hypertriglyceridemia (21, 78).”
BackgroundSHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855 · cited 1×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
ResultShimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13656 · Cited by 793 · cited 2×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
BackgroundResultLife without white fat: a transgenic mouse
Moitra, J., Mason, M. M., Olive, M., Krylov, D., Gavrilova, O., Marcus-Samuels, B., Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., et al. (1998) · Genes & Development · doi:10.1101/gad.12.20.3168 · Cited by 782 · cited 1×
“Studies in ob/ob and db/db mice (86), A-ZIP total lipodystrophic mice (87), and brown adipose tissue–deficient (BATless) (88) mice, all models of insulin resistance, have demonstrated increased hepatic expression of PPARγ and increased hepatic lipogenesis.”
BackgroundMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726 · cited 1×
“Troglitazone (12), Rosi (53), and Pio (13) have all been shown to have modest effects on the ability of insulin to suppress hepatic glucose production, but effects of TZDs on hepatic lipid metabolism are less well described.”
BackgroundGavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
Vidal-Puig, A., Jimenez-Liñan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S., & Moller, D. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118703 · Cited by 655 · cited 1×
“Studies in ob/ob and db/db mice (86), A-ZIP total lipodystrophic mice (87), and brown adipose tissue–deficient (BATless) (88) mice, all models of insulin resistance, have demonstrated increased hepatic expression of PPARγ and increased hepatic lipogenesis.”
Background
Research works printed but not linked: 3
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- Diraison, 1998, Am. J. Physiol., 274, E321
- Melish, 1980, Am. J. Physiol., 239, E354
Cited by
Items 101–200 of 202
Chatterji, S., & Fogel, D. (2018) · Integrative Medicine Research · doi:10.1016/j.imr.2018.04.002 · Cited by 31
Duez, H., Lamarche, B., Uffelman, K. D., Valéro, R., Szeto, L., Lemieux, S., Cohn, J. S., & Lewis, G. F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2110 · Cited by 26
“apoB) clearance via a mechanism postulated to be due to increased LPL mass and decreased apoC-III ( 9 ).”
BackgroundSelf-citationReyes, G., Yasunaga, K., Rothenstein, E., Karmally, W., Ramakrishnan, R., Holleran, S., & Ginsberg, H. N. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p700019-jlr200 · Cited by 25
Self-citationRana, H., Yadav, S. S., Reddy, H. D., Singhal, S., Singh, D. K., & Usman, K. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19887.8336 · Cited by 25
Reyes‐Soffer, G., Holleran, S., Karmally, W., Ngai, C. I., Chen, N.-T., Torres, M., Ramakrishnan, R., Blaner, W. S., Berglund, L., Ginsberg, H. N., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900092-jlr200 · Cited by 25
Self-citationNovel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus
Brouwers, M. C. G. J., Graaf, J. D., van Greevenbroek, M. M. J., Schaper, N. C., Stehouwer, C. D. A., & Stalenhoef, A. F. H. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ea9ec · Cited by 25
Impact of thiazolidenediones on serum lipoprotein levels
Goldberg, R. B. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0037-5 · Cited by 24
Reyes‐Soffer, G., Holleran, S., Tullio, M. R. D., Homma, S., Boden-Albala, B. M., Ramakrishnan, R., Elkind, M. S. V., Sacco, R. L., & Ginsberg, H. N. (2010) · Metabolism · doi:10.1016/j.metabol.2009.12.023 · Cited by 25
Self-citationNew treatments for chronic hepatitis C
Jang, J. Y., & Chung, R. T. (2010) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2010.16.3.263 · Cited by 21
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21
Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk
Millar, J. S. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283613a7d · Cited by 24
Small dense low-density lipoprotein-lowering agents
Alizadeh‐Fanalou, S., Nazarizadeh, A., Alian, F., Faraji, P., Sorori, B., & Khosravi, M. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0426 · Cited by 28
Millar, J. S., Lassman, M. E., Thomas, T. A., Ramakrishnan, R., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074880 · Cited by 22
Self-citationCombination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats
Refaat, R., Sakr, A., Salama, M. A., & Sarha, A. E. (2016) · Drug Development Research · doi:10.1002/ddr.21324 · Cited by 25
“The TG-lowering effect of pioglitazone has been attributed to increased plasma triglyceride clearance [Nagashima et al., 2005].”
BackgroundLavoie, F., Frisch, F., Brassard, P., Normand-Lauzière, F., Cyr, D., Gagnon, R., Drouin, R., Baillargeon, J., & Carpentier, A. C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1021 · Cited by 22
Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 22
Rizzo, M., Christ, E., Rini, G. B., Spinas, G. A., & Berneis, K. K. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.13.2295 · Cited by 19
“[59] reported that pioglitazone lowered triglyceride levels, at least in part, by increasing the fractional clearance of VLDLs and triglycerides from the circulation and attributed that change to an increased mass of lipoprotein lipase and reduced levels of apoC-III.”
BackgroundThiazolidinediones: Beyond Glycemic Control
Reynolds, K., & Goldberg, R. B. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605010-00004 · Cited by 21
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
Pathophysiologic, Diagnostic, and Therapeutic Aspects of the Metabolic Syndrome
Giles, T. D., & Sander, G. E. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04763.x · Cited by 29
Hamada, T., Kotani, K., Tsuzaki, K., Sano, Y., Murata, T., Tabata, M., Sato, S., & Sakane, N. (2007) · Metabolism · doi:10.1016/j.metabol.2007.05.017 · Cited by 19
van Wijk, J. P. H., Hoepelman, A. I. M., de Koning, E. J. P., Dallinga‐Thie, G. M., Rabelink, T. J., & Cabezas, M. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.216192 · Cited by 17
Tan, G. D., Olivecrona, G., Vidal, H., Frayn, K. N., & Karpe, F. (2006) · Diabetologia · doi:10.1007/s00125-006-0370-9 · Cited by 17
“Others have described increase of LPL mass in response to thiazolidinediones [26, 27].”
BackgroundFiévet, C., & Staels, B. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0043-5 · Cited by 19
“Mechanisms to explain this difference may relate to differential effects on LPL mass and apoC-III production [ 19 ], and on cholesterol-ester transfer protein activity [20].”
BackgroundGuías ALAD 2006 de diagnóstico control y tratamiento de la Diabetes Mellitus Tipo 2.
Alvarado, B., Arbañil, H., Arguedas, C., de Maza, M. A., Aylwin, C. G., Barragán, D., BENITEZ, A., Caballero, R. E., Calvagno, M., Chacra, A. R., et al. (2006) · Cited by 55
Brackenridge, A., Jackson, N., Jefferson, W., Stolinski, M., Shojaee‐Moradie, F., Hovorka, R., Umpleby, A. M., & Russell-Jones, D. L. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02729.x · Cited by 15
Wu, K. L. H., Wu, C., Tain, Y., Chao, Y., Hung, C., Tsai, P.-C., Wang, W.-S., & Shih, C.-D. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.013 · Cited by 17
Pioglitazone in diabetic kidney disease: forgotten but not gone
Papaetis, G. S. (2022) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/151046 · Cited by 17
“Arch Med Sci Atheroscler Dis 2022 e81 by approximately 12–30% and exerted a favourable effect on postprandial hypertriglyceridemia [8, 13, 66, 67].”
BackgroundEffects of Pioglitazone on Insulin Sensitivity and Serum Lipids in Obese Cats
Clark, M., Thomaseth, K., Dirikolu, L., Ferguson, D., & Hoenig, M. (2013) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12255 · Cited by 18
Takai, S., Jin, D., & Miyazaki, M. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11053fp · Cited by 16
Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL
Millar, J. S., Ikewaki, K., Bloedon, L. T., Wolfe, M. L., Szapary, P. O., & Rader, D. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p008136 · Cited by 15
Kassai, A., Muniyappa, R., Levenson, A. E., Walter, M. F., Abel, B. S., Ring, M., Taylor, S. I., Biddinger, S. B., Skarulis, M. C., Görden, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3891 · Cited by 15
Dorfmeister, B., Brandlhofer, S., Schaap, F. G., Hermann, M., Fürnsinn, C., Hagerty, B., Stangl, H., Patsch, W., & Strobl, W. (2006) · Diabetologia · doi:10.1007/s00125-006-0171-1 · Cited by 16
“In line with our observations are human data showing that pioglitazone significantly lowered plasma triglycerides in patients with type 2 diabetes, while plasma apoAV levels tended to decrease rather than to increase [43].”
ResultPeroxisome Proliferator‐Activated Receptors and Hepatitis C Virus‐Induced Insulin Resistance
Negro, F. (2009) · PPAR Research · doi:10.1155/2009/483485 · Cited by 14
“Activation of PPARα results in increased fatty acid β-oxidation in the liver [1], increased expression of HDL apolipoproteins Apo A-I and Apo A-II [2], inhibited expression of Apo C-III [3], increased lipoprotein lipase activity [4], and, therefore, increased VLDL and remnants clearance.”
Zhang, F., Sjöholm, Å., & Zhang, Q. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.103 · Cited by 14
PPARγ agonists and coronary atherosclerosis
Sulistio, M. S., Zion, A. S., Thukral, N., & CHILTON, R. J. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0020-4 · Cited by 14
“Nagashima et al. [ 43 ] evaluated changes in lipoprotein metabolism in T2DM patients receiving pioglitazone and proposed two major reasons for the lower triglyceride levels observed in the group receiving pioglitazone.”
BackgroundGim, H. J., Li, H., Jeong, J. H., Lee, S. J., Sung, M., Song, M., Park, B., Oh, S. J., Ryu, J., & Jeon, R. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.046 · Cited by 12
Peroxisome proliferator-activated receptors and hepatitis C virus
Eslam, M., Khattab, M. A., & Harrison, S. A. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11405251 · Cited by 14
“Increase glucose catabolism and decrease hepatic glucose output [Nagashima et al. 2005; Sakamoto et al. 2005).”
BackgroundInfluence of pioglitazone on experimental heart failure and hyperlipidemia in rats
Biswas, A., Rabbani, S., & Devi, K. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.96305 · Cited by 11
Abbasi, F., Lima, N. K. C., & Reaven, G. M. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.011 · Cited by 11
“kinetic studies by Nagashima and colleagues [24] in PIOtreated patients with 2DM indicated that the reason for the decrease in TG concentration was unlikely to be related to a decrease in hepatic VLDL-TG secretion, but rather the result of an increase in the fractional catabolic rate of VLDL-TG secondary to an increas…”
BackgroundThe good fat hormone: Adiponectin and cardiovascular disease
Do, D., Alvarez, J., Chiquette, E., & CHILTON, R. J. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0045-5 · Cited by 12
“This protein circulates at a relatively high level in healthy human subjects (2–10 �g/mL) [5], which can be increased by commonly used thiazolidinediones (TZD) and weight reduction [ 6 ].”
BackgroundGinsberg, H. N., & Ramakrishnan, R. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.174185 · Cited by 11
Self-citationWebb, M. D., Park, J. W., Day, D. B., Trabulsi, J., Sathyanarayana, S., & Melough, M. M. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae189 · Cited by 12
Iizuka, K., Hamaue, N., Machida, T., Hirafuji, M., & Tsuji, M. (2009) · Endocrine Research · doi:10.1080/07435800902889685 · Cited by 10
Using mass measurements in tracer studies—a systematic approach to efficient modeling
Ramakrishnan, R., & Ramakrishnan, J. D. (2008) · Metabolism · doi:10.1016/j.metabol.2008.03.011 · Cited by 9
“We have incorporated a module to do this automatically for our modeling program Poolfit [28], with provisions for the user to guide the dependency selection partially or totally.”
MethodResultInfluentialSelf-citationMechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes
Watts, G. F., & Chan, D. C. (2010) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2010.04.044 · Cited by 10
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.003 · Cited by 9
Park, J.-Y., Lee, J., Choi, Y., Min, K. W., Han, K. A., Ahn, K. J., Lim, S. K., Kim, Y., Ahn, C. W., Choi, K. M., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0259 · Cited by 8
Pioglitazone Decreases Plasma Angiotensin II Concentration inType 2 Diabetes
Saiki, A., Ohira, M., Endo, K., Koide, N., Oyama, T., Murano, T., Miyashita, Y., & Shirai, K. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.4002 · Cited by 7
Pioglitazone in the management of Type 2 diabetes and beyond
Sourij, H., & Wascher, T. C. (2007) · Therapy · doi:10.2217/14750708.4.5.517 · Cited by 7
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
Ginsberg, H. N., & Reyes‐Soffer, G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131333 · Cited by 7
Self-citationHabegger, K. M., Matzke, D., Ottaway, N., Hembree, J., Holland, J., Raver, C., Mansfeld, J., Müller, T. D., Pérez–Tilve, D., Pfluger, P. T., et al. (2012) · Adipocyte · doi:10.4161/adip.20891 · Cited by 6
Koide, N., Oyama, T., Miyashita, Y., & Shirai, K. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e511 · Cited by 8
The Role of Adiponectin in Atherosclerosis: do Lipids Tip the scales?
von Eynatten, M., & Schneider, J. G. (2005) · Future Cardiology · doi:10.2217/14796678.1.6.775 · Cited by 6
Triglycerides and Cardiovascular Disease : A Scientific Statement From the
Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6
Self-citationDrug Class Review: Thiazolidinediones
Norris, S. L., Carson, S., Thakurta, S., & Chan, B. K. S. (2008) · Cited by 6
Campbell, I. W. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050040601 · Cited by 6
Ramakrishnan, R. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.023 · Cited by 6
“A number of investigators have infused two amino acids simultaneously, sometimes both as constant infusions [1] and sometimes with one as a constant infusion and the other as a bolus [33-35].”
BackgroundSelf-citationReyes-Soffer, G., Liu, J., Thomas, T., Matveyenko, A., Seid, H., Ramakrishnan, R., Holleran, S., Zaghloul, N., Sztalryd-Woodle, C., Pollin, T., et al. (2023) · doi:10.1101/2023.06.23.23291823 · Cited by 6
Self-citationPPAR-γ agonists, insulin resistance and dyslipidemia: not a simple relationship
Johns, B., & Reaven, G. M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.36 · Cited by 5
Simonson, G. D., & Kendall, D. M. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000216965.36504.be · Cited by 5
Matsumoto, D., Yamanaka‐Okumura, H., Arai, H., Sakuma, M., Yamamoto, H., Taketani, Y., Tani, Y., Morine, Y., Shimada, M., & Takeda, E. (2007) · The Journal of Medical Investigation · doi:10.2152/jmi.54.375 · Cited by 5
Thiazolidinediones and vascular damage
Goldberg, R. B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328054c655 · Cited by 5
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.002 · Cited by 9
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_2 · Cited by 4
Self-citationHettihewa, L., Dharmasiri, L. P., Ariyaratne, C. D., Jayasinghe, S., Weerarathna, T., & Kotapola, I. (2007) · International Journal of Diabetes in Developing Countries · doi:10.4103/0973-3930.37042 · Cited by 4
Withdrawal of pioglitazone in patients with type 2 diabetes mellitus
Iwase, M., Asano, T., Sasaki, N., Yoshizumi, H., Hiramatsu, S., Sakai, Y., Ogo, A., & Iida, M. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01109.x · Cited by 4
Barnabas, R., Bhide, S. S., Memon, S. S., Karlekar, M. P., Phirke, C., Patil, S., Sekar, V., Shivane, V. K., Lila, A. R., & Bandgar, T. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103335 · Cited by 3
STOLAR, M. W. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2370 · Cited by 5
Aga, M., Arai, N., Ohashi, E., Ariyasu, T., Arai, S., Iwaki, K., Ohta, T., & Fukuda, S. (2009) · NIPPON SHOKUHIN KOGYO GAKKAISHI · doi:10.3136/nskkk.56.31 · Cited by 4
PPARγ (peroxisome proliferator-activated receptor gamma) receptor in diabetes mellitus
Sood, R., Mourya, A. K., Kumar, A., & Jeengar, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00010-5 · Cited by 3
Haiyan, W., Li, L., Lingling, Q., Dongchao, W., Yueying, J., Xinli, W., Xu, T., & Tonghua, L. (2017) · 中医杂志:英文版 · doi:10.1016/s0254-6272(17)30311-4 · Cited by 2
Lewis, G. F. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217906.36057.2b · Cited by 1
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-4 · Cited by 2
Self-citationGinsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_2 · Cited by 1
Self-citationGu, Y., Hu, A., Yamaguchi, T., Tabuchi, M., Ikarashi, Y., & Kobayashi, H. (2023) · Health · doi:10.4236/health.2023.1512086 · Cited by 1
Parmar, G. R., Chudasama, J. M., Maheshwari, R. A., Hinsu, D., Shah, A. P., Seth, A. K., & Balaraman, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04467-3 · Cited by 1
Ramakrishnan, R., & Ramakrishnan, J. D. (2010) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9522-7 · Cited by 1
“Lipoprotein kinetics are typically studied by a primed constant infusion of a labeled amino acid so that the precursor enrichment may be assumed to be constant (Nagashima et al., 2005; Tremblay et al., 2006).”
BackgroundMethodSelf-citationSpecial Patient Populations: Diabetes and Metabolic Syndrome
Kurra, S., Chahil, T. J., & Ginsberg, H. N. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50041-x · Cited by 1
Self-citationde Souza, N. C. G., Nunes, L. D. S., Martins, H. P. D. S., Percário, S., & Dolabela, M. F. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14149 · Cited by 1
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00035-9 · Cited by 1
Self-citationGinsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-3 · Cited by 1
Self-citationTherapeutic Regulation of High-Density Lipoprotein Transport in the Metabolic Syndrome
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1059-2_20 · Cited by 1
Reyes‐Soffer, G., Matveyenko, A., Lignos, J., Matienzo, N., Baez, L. S. S., Hernández‐Ono, A., Yung, L., Nandakumar, R., Singh, S. A., Ramakrishnan, R., et al. (2023) · medRxiv · doi:10.1101/2023.06.20.23291644 · Cited by 1
Self-citationLipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch17 · Cited by 1
Self-citationHettihewa, L. M., Dharmasira, L. P., Ariyaratne, C. D., Jayasinghe, S. S., Weerarathna, T. P., & Kotapola, I. (2009) · Galle Medical Journal · doi:10.4038/gmj.v12i1.1080
Rotllán, N., Escolá‐Gil, J. C., Calpe‐Berdiel, L., & Blanco‐Vaca, F. (2009) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(09)72685-3
Hettihewa, L. M., Dharmasiri, L. P., Weerarathna, T. P., & Kotapola, I. (2011) · Journal of Diabetes and Endocrinology · doi:10.5897/jde.9000020
Pioglitazone: lessons and learnings 15 years since launch and beyond
Stempa, O. (2015) · Diabetes Management · doi:10.2217/dmt.15.38 · Cited by 1
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American
Lennie, T. A., Levi, M., Mazzone, T., Pennathur, S., Goldberg, A. C., Howard, W. J., Jacobson, M. Z., Stone, N. J., Ballantyne, C. M., Bittner, V., et al. (2013)
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-1
Self-citationNew pharmacological approaches in type 2 diabetes mellitus
Cusi, K. J. (2009) · Dialnet (Universidad de la Rioja) · doi:10.1016/b978-84-8086-683-5.50016-0
Dissecting the role of apolipoprotein CIII in diabetic wound healing
Cho, M. M. W. (2019) · doi:10.32657/10220/48515 · Cited by 1
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280d5f7e9
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000235329.84906.3b
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-2
Self-citationProposed mechanisms of action of serum triglyceride lowering by plant sterols and stanols
Oranje, R. P. A. (2014) · Utrecht University Repository (Utrecht University)
Hypertriglycéridémie postprandiale : signature microARN et insulino-résistance
housseini, R. E. (2019) · theses.fr (ABES) · doi:10.70675/7d24ea93z83a6z478aza78dzaa7adafeb958
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Metadata
- Authors
- Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., & Ginsberg, H. N.
- Affiliations
- Columbia University (US)
- Cornell University (US)
- Montreal Clinical Research Institute (CA)
- Corresponding author
- Ginsberg, Henry N.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-04-01
- Volume
- 115
- Issue
- 5
- Pages
- 1323-1332
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1070635
- OpenAlex
- W2132525699
- Cited by
- 201
- References
- 104
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- Takeda Pharmaceuticals North America
- Deutsches Krebsforschungszentrum
- National Institutes of Health (RR-00645)
- National Heart, Lung, and Blood Institute (HL55368)
- National Center for Research Resources (RR 00645, M01RR000645)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, PPARγ agonists, type 2 diabetes, lipoprotein metabolism, VLDL triglycerides, lipoprotein lipase, apolipoprotein C-III, triglyceride clearance, lipolysis, insulin sensitivity
- MeSH terms
- Pioglitazone, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Female, Humans, Hypoglycemic Agents, Insulin, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Triglycerides, Intercellular Signaling Peptides and Proteins, Thiazolidinediones, PPAR gamma, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.